StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

412 Study Matches

Neural underpinnings of understanding speech in different listening contexts

This study evaluates the neural underpinnings of understanding speech in different listening contexts, such as listening to two talkers simultaneously or speech in background noise.

Melissa Polonenko
18 years and over
This study is also accepting healthy volunteers
STUDY00019631
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Group 1: Adults aged 18-70 years, normal hearing, proficient in spoken English
• Group 2: Adults aged 18-70 years, have hearing loss, proficient in spoken English
Exclusion Criteria:

• Neurological problems
• auditory neuropathy spectrum disorder (ANSD)
• Wear a cochlear implant
Ear, Nose & Throat
electrophysiology, hearing, hearing loss, listening, audible
I'm interested
Share via email

The Parallel Auditory Brainstem Response

This study aims to test the accuracy and speed of the pABR for future clinical use by recruiting adults with a range of hearing loss profiles from normal hearing to severe loss.

Melissa Polonenko
18 years and over
This study is NOT accepting healthy volunteers
SITE00001873
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 18-65 years
• hearing loss (can be from none to severe)
• no history of auditory neuropathy spectrum disorder or cochlear implant use
• can remain still or sleep for the test duration
Exclusion Criteria:

• profound hearing loss (thresholds > 80 dB HL)
• cochlear implant use
• auditory neuropathy spectrum disorder
• abnormal tympanogram
• inability to sleep or remain very still for the duration of the test
Ear, Nose & Throat
electrophysiology, Hearing, Hearing loss, Listening, audible
I'm interested
Share via email

A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 study Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)

The purpose of this research study is to determine if seladelpar (study drug) is effective at normalizing the disease marker alkaline phosphatase in subjects with PBC who are currently on ursodeoxycholic acid (UDCA) treatment or intolerant to UDCA. This will be done by looking at changes in blood tests. This research study is also measuring whether seladelpar makes itching (pruritus) better. This will be done using information about itching that subjects enter on a device or app on their phone.

Mary Thomson
18 years and over
This study is NOT accepting healthy volunteers
STUDY00020794
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 18 to 75 years old
• taking Ursodeoxycholic Acid (UDCA) for 12 months prior to screening (with stable dose for more than 3 months before starting the study) OR unable to take UDCA (last dose of UDCA greater than 3 months before starting the study)
• study staff will review additional inclusion and exclusion criteria
Exclusion Criteria:

• other chronic liver diseases
• drinking more than 2 drinks per day in women and 3 drinks per day in men, or unable to quantify alcohol intake reliably
• history of cancer diagnosed or treated, active or within 2 years, or ongoing evaluation for cancer; squamous or noninvasive basal cell skin cancers and cervical carcinoma in situ are allowed (if treated)
• women who are pregnant or plan to become pregnant, or are breastfeeding
Digestive & Liver Health
Clinics and Surgery Center (CSC), Primary Biliary Cholangitis
I'm interested
Share via email

A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 months to <24 months; mRNA-1365-P101

This study is recruiting children ages 5 months to less than 2 years learn about safety and effects of two Moderna study vaccines. The study vaccines are being designed to prevent respiratory tract infections caused by two common viruses, Respiratory Syncytial Virus (RSV) and Human metapneumovirus (hMPV). The child will be randomized to receive one of the two study vaccines or placebo. The placebo will look like the study vaccine but will not have a vaccine in it. The study lasts 24 months and the child will receive 3 injections with other study activities, such as blood draws and nose (nasal) swabs.

Shane McAllister
Up to 18 years old
This study is also accepting healthy volunteers
SITE00001862
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Ages 8 to 12 months at time of enrollment
Exclusion Criteria:

• Symptomatic RSV or hMPV infection since birth
• Previous hospitalization for respiratory illness
• Serious chronic illness, autoimmune disease, or neurological disorders
Children's Health, Infectious Diseases, Respiratory System
hMPV, immunization, infant, prevention, respiratory, RSV, vaccine, virus
I'm interested
Share via email
See this study on ClinicalTrials.gov

Time Restricted Eating as a Viable Alternative to Caloric Restriction for Treating Hyperglycemia in a Population with Type 2 (T2DM) diabetes (SFS3)

Feasibility study to test our overall hypothesis that time restricted eating (TRE) presents a viable alternative to caloric restriction for improving glycemic measures and reducing weight in overweight/obese patients with metformin-only treated Type 2 diabetes (T2DM).

Lisa Chow
18 years and over
This study is NOT accepting healthy volunteers
STUDY00014853
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• adults who are overweight/obese and have type 2 diabetes treated only with metformin
• 18-65 years old
• BMI between 25-40 kg/m2
• HbA1c between 6.5-8.5%
• self reported weight must be stable (+/- 5 pounds) for at least 3 months prior to the study
• own a smartphone
Exclusion Criteria:

• women who are pregnant or are planning to become pregnant
• eating disorders
Diabetes & Endocrine
time restricted eatin, Type 2 diabetes, diet intervention, intermittent fasting, caloric restriction
I'm interested
Share via email
See this study on ClinicalTrials.gov

JAK Inhibitors to Preserve C-Peptide Production in New Onset T1D: A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subtype-Selective JAK Inhibitors for Preservation of Pancreatic Cell Function in Newly Diagnosed Type 1 Diabetes Mellitus

This is a new type 1 diabetes onset study for ages 12-35 years old. We are looking at JAK inhibitor drugs to see if they can preserve beta cell function.

Antoinette Moran
Not specified
This study is NOT accepting healthy volunteers
SITE00001949
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 12-35 years (inclusive)
• diagnosis of T1D within 100 days of first study visit
• positive for at least one islet cell autoantibody
• HbA1c no more than 10 %
• body weight at least 35kg (77 pounds)
• willing to comply with intensive diabetes management and wear a Continuous Glucose Monitoring Device (CGM)
• up to date on recommended immunizations (including flu and COVID-19)
• willing to use highly effective contraception for 3 months after the last dose of study medication
Exclusion Criteria:

• current use of a medication that affects glucose control
• treatment with other immunosuppressive agents (including biologics or steroids), other than inhaled or topical glucocorticoids
• current history of infection (HIV, Hepatitis B, TB, herpes etc.)
• current or past use of tobacco or nicotine containing products more than the equivalent of 5 cigarettes per day
• current or past medical or mental health conditions (study staff will review)
• women who are pregnant, breast feeding, or planning to become pregnant
Children's Health, Diabetes & Endocrine
T1D, new onset, type 1 diabetes,
I'm interested
Share via email
See this study on ClinicalTrials.gov

Feasibility of conducting a pilot telehealth study assessing the removal of filter ventilation on smoking behavior and biomarkers in menthol smokers switched to non-menthol cigarettes

This study will examine how the design of the cigarette filter and menthol flavors affects smoking behavior, exposure to nicotine and the potential health effects from these exposures. The study will also evaluate how using the study cigarettes affects mood and responses to the cigarettes, such as tobacco satisfaction. In addition, we will assess how satisfied you are with participating in a completely remote (telehealth) research study.

Dorothy Hatsukami
18 years and over
STUDY00010212
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 21 years old
• in generally good health
• regularly smoke menthol cigarettes
• have daily access to a smartphone, tablet or computer with internet access
Exclusion Criteria:

• women who are pregnant, breast feeding or trying to become pregnant
Community Health, Respiratory System
cigarettes, Smoking
I'm interested
Share via email

MT2023-20: Hematopoietic cell transplant with reduced intensity conditioning and post-transplant cyclophosphamide for severe aplastic anemia and other forms of acquired bone marrow failure.

Although allogeneic hematopoietic cell transplant (HCT) is standard treatment for severe aplastic anemia, the use of the lower intensity conditioning drugs with a personalized dosing strategy, low dose total body irradiation (TBI) with dosing based on age and bone marrow abnormalities, and use of the drug cyclophosphamide early after transplant is a newer approach. We are studying whether this new approach is safer and more effective than our previous approach.

Christen Ebens
Not specified
This study is NOT accepting healthy volunteers
STUDY00021781
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 0 to 75 years old
• diagnosis of Idiopathic Severe Aplastic Anemia (SAA)
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• women who are pregnant, breastfeeding or intending to become pregnant during the study
• uncontrolled infection
Blood Disorders
Clinics and Surgery Center (CSC), Acquired Amegakaryocytic Thrombocytopenia, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, SA
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2022-45 Primary Immune Regulatory Disorders (PIRD): Longitudinal Study of Clinical Presentation, Treatment and Outcomes

Primary Immune Regulatory Disorders (PIRD disorders) are a group of diseases that cause the immune system to function abnormally and cause infections, autoimmunity or inflammation that can begin early in life. PIRD is usually caused by changes in genes in DNA. Researchers are trying to learn what types of medical problems patients with PIRD have and how these respond to treatment. Researchers also want to learn which genes cause PIRD and how it can cause the medical problems of PIRD.

Christen Ebens
Not specified
This study is NOT accepting healthy volunteers
SITE00001766
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 0 to 99 years
• diagnosis of immune-mediated bowel disease affecting at least one segment of the bowel
• evidence of interstitial lung disease (ground-glass opacities) or pulmonary nodules/cysts
• decreased lung function
• additional inclusion and exclusion criteria apply (study staff will review)
• also enrolling parent, sibling, or child of eligible participants
Exclusion Criteria:

• documented HIV infection
Rare Diseases
Clinics and Surgery Center (CSC)
I'm interested
Share via email

MT2022-44 Analysis of Autoinflammation in Chronic Granulomatous Disease Patients Undergoing Hematopoietic Cell Transplantation or Gene Therapy (PIDTC 6908)

CGD disorders are a group of diseases that cause the immune system to function abnormally, leading to infections, autoimmunity and/or inflammation that can begin early in life. CGD is usually caused by changes in certain genes in DNA. Researchers are trying to learn what types of medical problems patients with CGD have and how these respond to treatment, including bone marrow transplantation and gene therapy. Researchers also want to learn which genes cause CGD and how specific gene abnormalities lead to medical problems.

Christen Ebens
Not specified
This study is NOT accepting healthy volunteers
SITE00001764
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• confirmed diagnosis of Chronic Granulomatous Disease (CGD)
• to be scheduled to undergo HCT or GT within one year of enrollment
• additional inclusion criteria (study staff will review)
Exclusion Criteria:

• .presence of other primary immunodeficiency syndromes that do not meet the clinical and laboratory criteria for CGD
• HIV infection
• past or current medical problems or findings from physical examination or laboratory testing that are not listed above which, in the opinion of the investigator, may pose additional risks from participation
Cancer, Rare Diseases
Clinics and Surgery Center (CSC), CGD, Chronic Granulomatous Disease, Gene Therapy, GT, HCT, Hematopoietic Cell Transplant
I'm interested
Share via email

MT2021-29: Evaluation of intravenous laronidase pharmacokinetics before and after hematopoietic cell transplantation in patients with mucopolysaccharidosis type IH

In this study, the researchers are collecting blood samples to learn more about laronidase treatment in children that receive a hematopoietic cell transplantation. The laronidase dose regimens used after a hematopoietic cell transplantation may differ from those administered before. This study will establish the basis for determining if there is a need to adjust laronidase dosing regimens after receiving a hematopoietic cell transplantation.

Silvia Illamola
Up to 18 years old
This study is NOT accepting healthy volunteers
STUDY00016560
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• between 0 to 3 years of age
• meet protocol specific eligibility criteria for allogeneic HCT for MPS IH
• planning to receive laronidase both pre and post-transplant in an inpatient setting as part of standard-of-care treatment. Virtually all patients with MPSIH being considered for transplantation at the University of Minnesota are already receiving enzyme infusions, and it is standard practice to continue to give enzyme infusions to 8 weeks post-transplant. Therefore, participation will not modify the treatment course
Exclusion Criteria:

• patient's parent/ legal guardians are unable to provide informed consent.
Rare Diseases, Cancer
Hematopoietic Cell Transplantation
I'm interested
Share via email
See this study on ClinicalTrials.gov

Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in at-risk Older Adults (The Exergames Telerehabilitation Study)

The purpose of this study is to test the effects of an in person or home-based exergame intervention on improving cognition and fitness in community-dwelling older adults with memory complaints. The exergame refers to a new low-cost virtual reality cognitive game with cycling. We expect that participants will be in this research study for 4 months. Intervention sessions will require approximately 1 hour, 3 days per week for 3 months.

Dereck Salisbury
18 years and over
This study is NOT accepting healthy volunteers
STUDY00020635
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 65 years old
• experiencing a memory or cognitive problem
• speak English
• no physical problems that prevent exercise
Exclusion Criteria:

• diagnosis of dementia or mild cognitive impairment
• neurological or major psychiatric disorder, alcohol/chemical dependency or recent medical condition (anesthesia or COVID-19 brain fog) likely causing cognitive impairment
• currently enrolled in another clinical study
Brain & Nervous System, Community Health
cognitive, exercise, Memory
Visit study website
I'm interested
Share via email

Humanitarian Use Device: Medtronic DBS Therapy for Dystonia (HDE #H020007) (Dystonia IRB)

Humanitarian use devices are medical devices approved by the FDA for the treatment of medical conditions affecting fewer than 4,000 patients per year. The FDA reviewed the safety of the device and determined that the probable health benefits outweigh the risks of injury or illness from its use. Effective treatment of symptoms, however, has not been studied in formal clinical trials. Medtronic DBS Therapy delivers electrical stimulation to areas in the brain to help control symptoms of various movement disorders. You may be a candidate for Medtronic DBS Therapy for Dystonia if you have been diagnosed with chronic, intractable (drug refractory) primary dystonia. You or your third party payer (health insurance, Medicare, Medicaid or other) must provide payment for hospital, office and other medical costs related to this therapy.

Jerrold Vitek
This study is NOT accepting healthy volunteers
1207M17701
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 7 to 99 years old
• diagnosed with chronic, intractable (drug refractory) primary dystonia determined by a neurologist or neurosurgeon
Exclusion Criteria:

• patients who are at significant surgical risk as determined by the neurosurgeon and/or anesthesiologist
• patients who have not had an adequate trial of medical or non-surgical treatment
Brain & Nervous System
DBS, Deep Brain Stimulation, Dystonia
I'm interested
Share via email
See this study on ClinicalTrials.gov

Udall P1A4

Through this research, the study staff hopes to better understand how DBS works and to define the optimal site in the brain for DBS treatment for Parkinson’s Disease. You will be asked to come for one study visit where you will perform some physical and mental tasks while on and temporarily off your medications and DBS treatment. Participation in this research study will take 7-8 hours.

Jerrold Vitek
Not specified
This study is NOT accepting healthy volunteers
STUDY00019735
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 10 years old
• diagnosis or suspected diagnosis of Parkinson's disease, Essential Tremor, or Dystonia
• implanted Deep Brain Stimulator (DBS)
• have a 7T MRI
Exclusion Criteria:

• history of dementia
• women who are pregnant or breastfeeding
• other exclusion criteria (study staff will review)
Brain & Nervous System
DBS, Dystonia, Essential Tremor, ET, Movement Disorders, Parkinson's, Parkinson's Disease, PD
I'm interested
Share via email
See this study on ClinicalTrials.gov

Circuit-Based Deep Brain Stimulation for Parkinson's disease; Udall Clinical Core

The goal of this study is to provide comprehensive longitudinal assessments of a cohort of PD patients before, during, and after DBS surgery, including neurological, neurophysiological, and neuropsychological data.

Scott Cooper
18 years and over
This study is NOT accepting healthy volunteers
1611M00822
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 21 years and older
• diagnosis of Parkinson's disease
• candidate for DBS
Exclusion Criteria:

• diagnosis of dementia
• women who are pregnant
Brain & Nervous System
Clinics and Surgery Center (CSC), DBS, Deep Brain Stimulation, Parkinson's Disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

TMS x DPX

We will examine whether the benefits of brain stimulation on mental functioning can be enhanced if an individual is actively engaging the target brain networks while receiving brain stimulation. The study includes two separate sessions and people will complete either a cognitive task or a perceptual task while we are measuring the change in brain function with EEG. Please fill out the linked screening questionnaire to determine if you are eligible.

Alik Widge
18 years and over
This study is also accepting healthy volunteers
STUDY00019156
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 18 to 65
Exclusion Criteria:

• diagnosed with a psychiatric disorder
• potential contraindications to EEG (e.g. visible scalp abrasions, non-removable hair extensions and/or hair styling that would impede proper EEG recording)
• potential contraindication to TMS (as identified by the TMS safety screener)
• any previous adverse reaction to TMS or MRI
• diagnosed with epilepsy or previously experienced a seizure
• diagnosed with a neurological condition, such as stroke or tinnitus
• experienced a head trauma that was diagnosed as concussion
• current use of, or recent withdrawal from, medications that can increase the risk of seizure
• currently pregnant
• any metal in the head (excluding mouth) or have an implanted medical device
Mental Health & Addiction
cognition, EEG, rTMS
Visit study website
I'm interested
Share via email

COG AGCT1532 - A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors (P3BEP)

This trial is an open label, randomized, stratified 2-arm Australian-led multicenter phase 3 clinical trial undertaken in two stages. Participants (age >= 11 years and <= 45 years) with intermediate and poor-risk metastatic germ cell tumors will be randomized into either a “standard BEP” group or “accelerated BEP” group. Participants will be assigned to the two treatment arms in a 1:1 ratio and evaluated weekly, and then for 5 years after completing the study to assess the long-term effects of the chemotherapy. Bleomycin, Etoposide, Cisplatin (BEP) administered 3-weekly x 4 remains standard 1st line chemotherapy for intermediate- and poor-risk metastatic germ cell tumours (GCTs). BEP is accelerated by cycling Cisplatin and etoposide 2-weekly instead of 3-weekly. The aim of this study is to determine if accelerated BEP is superior to standard BEP as first-line chemotherapy for intermediate and poor risk metastatic GCTs.

Brenda Weigel, MD, MSc
Not specified
This study is NOT accepting healthy volunteers
SITE00000331
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• between 11 years and 45 years old
• confirmed germ cell tumour (non-seminoma or seminoma) OR Exceptionally raised tumour markers (AFP equal or greater than 1000ng/mL and/or HCG equal or greater than 5000 IU/L)
• primary arising in testis, ovary, retro-peritoneum, or mediastinum
• metastatic disease or non-testicular primary
• see link to clinicaltrials.gov for completed Inclusion/Exclusion criteria
Exclusion Criteria:

• other primary malignancy (EXCEPT adequately treated non-melanomatous carcinoma of the skin, germ cell tumour, or other malignancy treated at least 5 years previously with no evidence of recurrence)
• significant cardiac disease resulting in inability to tolerate IV fluid hydration for cisplatin
• peripheral neuropathy equal or greater than grade 2 or clinically significant sensorineural hearing loss or tinnitus
Cancer
Germ Cell Tumor
I'm interested
Share via email
See this study on ClinicalTrials.gov

Frailty Assessment by Edmonton Frail Scale to Predict Outcome in Patients Undergoing Cardiovascular Surgery "Frail Heart" Study

We are looking at measures of frailty (including an assessment questionnaire and other data from the medical record) and the relationship to outcomes from cardiac or vascular surgery. The questionnaire will take about 10 minutes to complete and we will contact you by phone once every three months for one year after your surgery.

Tjorvi Perry
18 years and over
This study is NOT accepting healthy volunteers
STUDY00009831
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
People who are having any of the following heart surgery procedures:
• thoracic aortic surgery
• coronary artery bypass graft surgery
• Aortic valve replacement
• Mitral valve replacement or repair
• Tricuspid valve replacement or repair
• Pulmonary valve replacement
• Infective endocarditis surgery
• Open and interventional abdominal aortic revascularization
Exclusion Criteria:

• People who have liver cirrhosis
• People who aren't able to make independent health care decisions
Heart & Vascular
Cardiac Surgery, Coronary Artery Bypass, Heart Valve Replacement, Abdominal Aortic Surgery
I'm interested
Share via email

SKOAP: A Sequenced-Strategy for Improving Outcomes in people with knee OsteoArthritis Pain (SKOAP)

There is an urgent public health need to reduce our reliance on opioids for effective long-term pain management, particularly in knee osteoarthritis (KOA). This effectiveness trial will compare recommended treatments to reduce pain and functional limitations in KOA and identify clinical and patient-level factors associated with treatment response. These results will lead to improved patient selection for treatment and inform evidence based guidelines by offering well-tested, effective, non-opioid alternatives.

Clarence Shannon
18 years and over
This study is NOT accepting healthy volunteers
SITE00000944
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• have osteoarthritis of a knee(s)
Exclusion Criteria:

• scheduled knee replacement surgery or history of knee replacement in the painful knee
• medical condition that prevents exercise
• untreated bleeding disorder
• ulcers or an open wound near the knee
Arthritis & Rheumatic Diseases
arthritis, knee pain, osteoarthritis
I'm interested
Share via email
See this study on ClinicalTrials.gov

SPR001-205 A Phase 2 Study to Evaluate the Safety, Pharmacokinetics,;and Exploratory Pharmacodynamics of SPR001 (Tildacerfont) in Children: Aged 6 to 17 Years with Congenital Adrenal Hyperplasia

The goal of this study is to test the safety and effectiveness of tildacerfont in children with congenital adrenal hyperplasia (CAH). When a child is enrolled in the study, in addition to taking the study drug (tildacerfont), he or she will continue to take his or her standard glucocorticoid doses. A part of the study will be to test different doses of the study drug and to measure adrenal hormones at each visit. Children will be in the study for 18 weeks and will have to visit the study clinic 5 times.

Kyriakie Sarafoglou
Up to 18 years old
This study is NOT accepting healthy volunteers
SITE00001409
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 2 to 17 years
• childhood diagnosis of classic congenital adrenal hyperplasia (CAH) a genetic mutation in CYP21A2
• currently taking steroids to treat CAH and on a stable dose for 1 month or more
Exclusion Criteria:

• clinically significant unstable medical or mental health condition (study staff will review)
• females who are pregnant or nursing
• unable to swallow medications
Rare Diseases, Children's Health
CAH, Congenital Adrenal Hyperplasia
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2023-30: A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors

The purpose of this study is to test the safety of FT825 at different doses and to understand the way the body processes and responds to FT825. The study will also find out what effects FT825, when given with or without a monoclonal antibody (cetuximab) and different chemotherapy regimens, have on cancer. FT825 is a type of cell product made up of “T cells.” T cells are part of your immune system and are important in helping fight infections. T cells are also important in eliminating cancer cells.

Manish Patel
18 years and over
This study is NOT accepting healthy volunteers
SITE00002088
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis locally advanced or metastatic cancer
• cancer that is not amenable to curative therapy, with prior therapies defined by specific tumor types
• restricted from strenuous activity but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• women who are pregnant or breastfeeding
• active central nervous system (CNS) involvement by cancer -active bacterial, fungal, or viral infections
• additional exclusion criteria (study staff will review)
Cancer
Clinics and Surgery Center (CSC), Metastatic Cancer, Solid Tumor Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

Feasibility of a text message intervention in Hmong community

We are conducting this research to better understand if text messages can be used for diabetes education for patients in the Hmong community. People will be in this research study for one month. You will receive two text messages per week for one month and be asked to complete a 5-10 minute survey at the end of the month.

Katherine Montag-Schafer
18 years and over
STUDY00021632
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• identify self as Hmong
• have diabetes
• receive care at the Phalen Village Clinic
• have a cell phone that can receive text messages
Exclusion Criteria:

• under 18 years old
Diabetes & Endocrine
Diabetes, Hmong
I'm interested
Share via email

COLLABS: Colorectal Cancer Legal and Administrative Burden Support: A Pilot Clinical Trial

The purpose of this research is to determine the impact of providing personalized legal and financial services on the financial and emotional health of people with advanced stage colorectal cancer. We have partnered with a local nonprofit company called Cancer Legal Care (CLC) to provide the legal and financial services that people will receive as part of this research.

Arjun Gupta
18 years and over
This study is NOT accepting healthy volunteers
STUDY00021793
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of advanced stage colorectal cancer
• receiving care at the Masonic Cancer Center
• able to understand, speak, read, and write in English
Exclusion Criteria:

• lack capacity to consent
Cancer
Colon cancer, legal care
I'm interested
Share via email

Sleep Outcomes with DBS Therapy in Parkinson's Disease and Dystonia

The objective of this study is to describe how activation of distinct pathways in and around the subthalamic nucleus (STN) and internal segment of the globus pallidus (GPi) correlate to changes in sleep outcomes in movement disorders patients after deep brain stimulation (DBS) surgery targeting these structures.

Luke Johnson
18 years and over
This study is NOT accepting healthy volunteers
STUDY00018981
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 21 years old
• existing or planned 7T brain imaging
• surgery at UMN to implant DBS system planned as part of routine clinical care (or has already occurred, as long as the first programming session is at least 2 weeks away)
Exclusion Criteria:

• other significant neurological disorder
• history of dementia
• complications after surgery
• women who are pregnant
Brain & Nervous System
Clinics and Surgery Center (CSC), DBS, Parkinson's Disease, Sleep Apnea
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2021-24: A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Adult Patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie

The purpose of the study is to determine the safety and effectiveness of a new procedure to treat Mucopolysaccharidosis Type I Hurler-Scheie and Scheie (MPS I). This procedure involves collecting some white blood cells (termed “B cells”) and growing them outside of the body in a laboratory. While the cells are in the lab, the B cells will be changed to produce more of the IDUA that is missing. This process is called “genetic modification.” The newly modified B cells are then infused back into the participant.

Paul Orchard
18 years and over
This study is NOT accepting healthy volunteers
STUDY00016974
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of Mucopolysaccharidosis type I Hurler-Scheie or Scheie syndrome
• creatinine clearance, calculated or measured directly, that is greater than 60ml/min/1.73m2
• ejection fraction at least 40% by echocardiogram
• must agree to stay <45-minute drive from the study site for a minimum of 5 days after cell infusion.
• must commit to traveling to the study site for the necessary follow-up evaluations.
Exclusion Criteria:

• known family inherited cancer syndrome
• had a previous hematopoietic stem cell transplant (HSCT)
• any medical condition likely to interfere with assessment of safety or efficacy of the study treatment (study staff will review)
Rare Diseases
Mucopolysaccharidosis IH/S, Mucopolysaccharidosis IS
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2024-05: A Phase I, First in Human Open Label Study to Evaluate the Safety and Tolerability of TRX103 cell infusion in subjects with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT)

This study will enroll patients with a blood cancer who need to undergo a stem cell (bone marrow) transplant using a donor that is not a full DNA match with them. It tests TRX103, a cellular therapy, to see if it is an effective and safe way to prevent Graft versus Host Disease (GvHD), a common and potentially serious side effect of stem cell transplant.

Mark Juckett
18 years and over
This study is NOT accepting healthy volunteers
STUDY00021552
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• undergoing mismatched related (haploidentical) or unrelated allogeneic hematopoietic stem cell transplantation (HSCT)
• diagnosis of one of the following hematologic malignancies: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), or Chronic myelomonocytic leukemia (CMML)
• weight is at least 35 kgs (77 pounds)
• available mismatched related (haploidentical) or unrelated donors for peripheral blood stem cell (PBSC) donation
• study staff will review additional inclusion and exclusion criteria
Exclusion Criteria:

• prior allogeneic bone marrow, peripheral blood, or cord blood HSCT
• HIV positive, positive hepatitis-B surface antigen or positive hepatitis-C antibody (unless treated)
• women who are pregnant, breast feeding or aim to become pregnant during the study period
Cancer
blood cancer, hematopoietic stem cell transplantation (HSCT)
I'm interested
Share via email
See this study on ClinicalTrials.gov

Assessment of usability and satisfaction with a take-home device presenting sound and body stimulation for back pain

The purpose of this study is to measure the compliance, usability, and satisfaction of an at-home, multi-modal stimulation device in a diverse population of people with chronic lower back pain (cLBP) compared to a group of participants who are engaging in integrative health practices. The multi-modal device will include a combination of electrical stimulation, auditory stimulation, and integrative-health techniques, including mindfulness breathing, health coaching, and reflective journaling. The multi-modal device creation is based on prior knowledge in lower back pain treatment, which includes electrical stimulation of the back (Transcutaneous Electrical Nerve Stimulator or TENS) and integrative health modalities. Findings from this usability pilot study could help refine the approach and the multi-modal device for a future intervention study in cLBP participants.

Hubert Lim
18 years and over
This study is NOT accepting healthy volunteers
STUDY00021883
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• must have chronic lower back pain, defined as back pain lasting 3 or more months, - willing to travel to the University of Minnesota and commit to the study duration
Exclusion Criteria:

• cannot have any implanted stimulation devices
Bone, Joint & Muscle
Back Pain
I'm interested
Share via email

Visual Perception in Visual Snow Syndrome

This study seeks to understand visual perception in people with Visual Snow Syndrome and how this relates to brain function.

Michael-Paul Schallmo
18 years and over
This study is NOT accepting healthy volunteers
STUDY00014113
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
? Between 18 - 60 years old ? Good general physical health ? No history of other neurological disorders or problems ? Fluent in English
Vision & Eyes
Visual snow, visual snow syndrome
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2023-10: A Phase 1 Study of FT522 in Combination with Rituximab in Participants with Relapsed/Refractory B-Cell Lymphoma

We are studying FT522 - a new product that is made by modifying cells in a laboratory - both with and without additional drugs, to see if it can help treat people with B-cell lymphoma. This study is for people who have had at least one treatment for their lymphoma, but the cancer either returned or did not respond to the treatment. We are testing this product to see what side effects it might have, as well as to see whether it is effective at treating B-cell lymphoma.

Veronika Bachanova, MD
18 years and over
This study is NOT accepting healthy volunteers
SITE00001976
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of B-cell lymphoma (BCL)
• at least 1 prior systemic regimen of treatment
• men and women participants of childbearing potential who engage in heterosexual intercourse must agree to use specified method(s) of contraception
Exclusion Criteria:

• women who are pregnant or breastfeeding
• capable of only limited selfcare; confined to bed or chair more than 50% of waking hours
• body weight less than 50 kg (110 lb.)
• additional medical diagnosis (study staff will review)
Cancer
Clinics and Surgery Center (CSC), Lymphoma, Relapsed/Refractory B-Cell Lymphoma
I'm interested
Share via email
See this study on ClinicalTrials.gov

A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA)

The purpose of the study is to see if ianalumab, compared to placebo, is effective and safe for treating wAIHA. A placebo looks like the study drug, ianalumab, but does not contain any active ingredient. Ianalumab belongs to a class of drugs called monoclonal antibodies. Monoclonal antibodies are molecules that can recognize and stick to a specific protein expressed on the cell surface or released free in the body. Participants will receive study drug (ianalumab or placebo) through the vein every 4 weeks (4 doses in total) during the treatment period.

Marshall Mazepa, MD
18 years and over
This study is NOT accepting healthy volunteers
STUDY00018783
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• people with documented primary or secondary wAIHA
• had an insufficient response to or relapsed after one or more treatments
• Hemoglobin concentration at screening between 5 g/dL and 10 g/dL and experiencing symptoms of anemia
• dose of supportive medication must be stable for at least 4 weeks
Exclusion Criteria:

• wAIHA due to disease involving bone marrow
• prior use of B-cell depleting therapy (e.g., rituximab) within 12 weeks prior to starting the study
• active viral, bacterial or other infections that require systemic treatment at time of screening, or a history of recurrent clinically significant infection
• positive for hepatitis C virus, hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb)
• contact study staff for additional criteria
Blood Disorders
hemolytic anemia, wAIHA, warm autoimmune hemolytic anemia
I'm interested
Share via email